LETTER TO THE EDITOR

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/re lapse acute leukemias of ambiguous lineage, not otherwise specified

Kaiqi Liu, Yan Li, Shaowei Qiu, Chunlin Zhou, Shuning Wei, Dong Lin, Guangji Zhang, Hui Wei, Ying Wang, Bingcheng Liu, Xiaoyuan Gong, Qiuyun Fang, Yang Song, Huijun Wang, Chengwen Li, Qinghua Li, Lihua Wu, Benfa Gong, Yuntao Liu, Jianxiang Wang* and Yingchang Mi*

Abstract
Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging. Traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our hospital, who were treated with venetoclax based treatment (venetoclax combining with azacitidine or chemotherapy). All 6 patients achieved CR. Five of the six patients received allo-HSCT, four patients were still alive in CR until the follow-up day. Our data provide preliminary evidence and show that venetoclax based regimens are effective and safety in patients with R/R ALAL-NOS.

Keywords: Efficacy, venetoclax, ALAL-NOS, Relapse, Refractory

Letter to the editor
Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is an extremely rare type of acute leukemia. The induction therapy for ALAL-NOS often refers to ALAL treatment. The outcome of ALAL (especially mixed phenotype acute leukemia, MPAL) was improved by acute lymphoblastic leukemia (ALL)-like therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) during the first complete remission (CR1) [1–6]. However, salvage treatment of relapse/refractory (R/R) ALAL-NOS remain major concerns. Allo-HSCT is the only available cure for ALAL-NOS, but the outcome remains poor if the patient did not achieve CR before allo-HSCT [6]. Traditional chemotherapy is not effective. Therefore, other salvage therapies are needed to improve the CR before allo-HSCT.

Venetoclax, a potent oral inhibitor of BCL-2, has demonstrated clinical efficacy in various hematological malignancies [7, 8]. It can be combined with hypomethylating agents (HMAs), low-dose cytarabine (LDAC) and dose-reduced IA (idarubicin + Ara-c) in the treatment of newly diagnosed acute myeloid leukemia (AML), and achieve ideal effect [9–11]. Some case reports showed that venetoclax was effective in mixed phenotype acute leukemia (MPAL) [12]. Herein, we evaluated the therapeutic effect of venetoclax-based treatment in six R/R ALAL-NOS patients at our institution.

Between September 2017 and July 2020, six R/R ALAL-NOS patients at our hospital, who fulfilled the criteria of ALAL-NOS according to the 2016 World Health Organization (WHO) classification, were treated with venetoclax-based regimen (venetoclax

*Correspondence: wangjx@ihcams.ac.cn; miyingchang1@126.com
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
combined with azacitidine or chemotherapy. The diagnosis was based on morphology, cytochemistry, immunophenotype, cytogenetic and molecular results. Fluorescence in situ hybridization (FISH) analysis for BCR-ABL, p53 deletion and MLL rearrangements were performed at the time of diagnosis. Data of the six patients was collected and analyzed, including clinical characteristics, cytogenetics, gene mutation profile, prior therapy, complete remission (CR) rate, overall survival (OS, survival duration was defined from diagnosis of the disease to dead).

Characteristics of the six patients are shown in Table 1. There were two women and four men, with a median age of 26 years (range, 16–66). Normal karyotype was found in three cases. Abnormalities involving MLL gene at the 11q23 locus were found in one case by FISH. Mutational analysis by next-generation sequencing showed mutations such as PHF6, NOTCH1, FAT1, BCOR, IKZF1, PTPN11, NRAS, etc., which were commonly seen in ALL (especially in T-ALL); mutations associated with AML such as FLT3/ITD, TET2, DNMT3A, NPM1, IDH2 and IDH1 were not found. One patient (patient 1) had RUNX1 mutation. The immunophenotype by FACS and cytochemical staining of the 6 ALAL-NOS patients was listed in (Additional file 1: Table S1). Patient 1 relapsed after allo-HSCT and patients 2–6 were refractory to at least one cycle traditional induction chemotherapy. All six patients were re-induced with venetoclax-based regimen (Table 2). Venetoclax was initiated at 100 mg daily and ramped up to 400 mg daily within three days, with continuous administration for 28 days. AZA was subcutaneously administered at 75 mg/M² daily for seven days in patient 1. She achieved CR after one course of treatment, without another allo-HSCT, patient relapsed after CR for nine months, and died of disease progression. The other five refractory patients were treated with venetoclax combined with chemotherapy (detailed chemotherapy regimens are shown in Table 2). Venetoclax was initiated at 100 mg daily and ramped up to 200–400 mg daily within three days, chemotherapy was started on the fourth day (venetoclax dose was 200 mg/day due to combination with voriconazole for patient 4). Venetoclax was administered for ≥14 days. After one

| Table 1 | Clinical characteristics at diagnosis of the 6 R/R ALAL-NOS patients |
|---------|------------------------------------------------------------------|
| No.     | Sex | Age (y) | Diagnosis | WBC (10⁹/L) | BM blast cell (%) | Chromosome | Fish | Gene mutation(NGS) |
|---------|-----|---------|-----------|-------------|-----------------|------------|------|-------------------|
| 1       | F   | 66      | ALAL-NOS  | 3.37        | 87.0            | 46,XX      | Negative | RUNX1, FAT1, BCOR |
| 2       | M   | 16      | ALAL-NOS  | 25.18       | 91.50           | 46,XY; t(10;12)(p11.2;q15), inc[4]/46,XY | Negative | PHF6, NRAS, RAD21, CALR |
| 3       | M   | 23      | ALAL-NOS  | 62.9        | 83.5            | 46,XY      | Negative | PHF6, IKZF1, KMT2D, WT1, PTPN11, EED |
| 4       | M   | 29      | ALAL-NOS  | 2.36        | 68.0            | 46,XY      | MLL(+)   | IL7R               |
| 5       | F   | 52      | ALAL-NOS  | 5.57        | 73.5            | 46,XX;del(22)(q13)[3]/46,XX;del(8)(p21),del(22)(q13)[15]/46,XX;del(3,6);del(8)(p21);del(22)(q13)[1]/46,XX[1] | Negative | BCOR |
| 6       | M   | 22      | ALAL-NOS  | 55.5        | 79.0            | 47,XY;del(5)(q31),del(13)(q12q22),+mar[20] | Negative | NOTCH1, KMT2C, PTPN11, TP53 |

| Table 2 | Initial treatment, salvage therapy and outcome of 6 R/R ALAL-NOS patients |
|---------|----------------------------------------------------------------------|
| No.     | Previous treatment | Reinduction treatment | VEN dose, (mg) | VEN days | Response to VEN combination | HSCT | Outcome | OS (m) |
|---------|-------------------|----------------------|----------------|----------|-----------------------------|------|---------|--------|
| 1       | Chemotherapy and HSCT | VEN + AZA | 400 mg | 28d | CR | N | Dead | 36 |
| 2       | VDCP NR, DAC + HACVP NR | VEN + AAVP | 400 mg | 14d | CR | Y | CR | 15 |
| 3       | VDCP NR, DAC + HACVP NR | VEN + AAVP PR, DAC + VEN + AAVP | 400 mg | 21d | CR | Y | Dead | 9 |
| 4       | DAC + AAVP NR | VEN + HOAP | 200 mg (with voriconazole) | 14d | CR | Y | CR | 8 |
| 5       | VDCP + AA NR | VEN + CA | 400 mg | 14d | CR | Y | CR | 7 |
| 6       | AACVP NR | VEN + HOAP | 400 mg | 14d | CR | Y | CR | 5 |

VEN, venetoclax; DAC, decitabine; AZA, azacitidine; VCR, vincristine; DNR, daunorubincin; CTX, cyclophosphamide; Pred, prednisone; HHT, homoharringtonine; Ara-c, cytarabine; Acla, aclacinomycin; VDCP, VCR + DNR + CTX + Pred; HACVP, HHT + Ara-c + CTX + VCR + Pred; AAVP, Aca + Ara-c + VCR + Pred; AA, Acla + Ara-c; CA cladribine + LDAC; AACP, Acla + Ara-c + CTX + VCR + Pred; HOAP, HHT + Ara-c + VCR + Pred; HSCT, hematopoietic stem cell transplantation
course of treatment, three patients (patients 2, 5 and 6) achieved CR; one patient (patient 4) achieved CRi; one patient (patient 3) achieved PR. Patient 3 was retreated with the same regimen plus decitabine and subsequently achieved CR. Patients 2–6 received allo-HSCT after achieving CR. On May 1, 2021, the median follow-up time was 8.5 months (range, 5–36). Four patients remained in CR; while one patient (patient 3) died of 4-degree GVHD after allo-HSCT.

No tumor lysis was observed. The most common non-hematological adverse events were Grade 2/3 nausea and vomiting. All the patients had Grade 3/4 hematological toxicity, including leucopenia, neutropenia and thrombocytopenia. However, no patient had venetoclax dose interruptions, or experienced major bleeding or serious infections.

Treatment of ALAL-NOS remains a challenge, especially for relapse/refractory patients. Traditional induction chemotherapy is ineffective. In this report, six R/R ALAL-NOS patients were treated with venetoclax-based therapy (combined with azacitidine or chemotherapy). All six patients achieved CR. Five of the six patients received allo-HSCT, of which four patients remained alive in CR at the final follow-up, one patient died of serious GVHD after transplantation. Patient 1 who did not receive allo-HSCT died of disease progression.

Although the number of patients in this study was limited, the data provided preliminary evidence that venetoclax-based regimens are effective and safe in patients with refractory or relapsed ALAL-NOS. Venetoclax-based regimens should be tested and verified as high-efficacy initial induction therapy for ALAL-NOS.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40164-021-00239-w.

Additional file 1: Table S1. The immunophenotype by FACS and cytochemical staining of the ALAL-NOS patients. Table S2. The duration from CR to transplant and maintenance treatment of 6 R/R ALAL-NOS patients.

Acknowledgements
Not applicable.

Author’s contributions
KL and YL collected the data and wrote the manuscript. SQ, CZ, SW, DL, GZ, HW, YW, BL, XG, QF, YS, LW, BG, and YL were involved in patient management and clinical data collection. YM and JW revised the manuscript and provided valuable advice. HW performed the majority of FACS analysis. CL performed the cytogenetic analysis. QL was responsible for the molecular analysis. All authors read and approved the final manuscript.

Funding
This study was supported by the National Key Research and Development Program of China (2019YFC0804060), the National Science and Technology Major Project (2017ZX09304024), and the National Natural Science Foundation (81800173).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
All studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the Helsinki Declaration 2013. Written informed consent was obtained from the patients or patients’ parents/legal guardians.

Consent for publication
All authors have read and approved the manuscript for publication.

Competing interest
The authors have no competing interests to declare.

Received: 6 July 2021 Accepted: 28 August 2021
Published online: 16 September 2021

References
1. Hyun GL, Hee JB,Ho SK, Soo M, Tai JH, Hoon K. Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome. Blood Res. 2019;54:63–73.
2. Orgel E, Alexander TD, Wood BL, Kawashv SE, Devidas M, Dai Y, et al. Mixed-phenotype acute leukemia: a cohort- and consensus research strategy from the children’s oncology group acute leukemia of ambiguous. Lineage Task Force. Cancer. 2020;126(3):593–601.
3. Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood. 2015;125:2477–85.
4. Olga ZS, Ninela IJ, Elżbieta D, Katarzyna MR, Maryna KR, Joanna Z, et al. Mixed phenotype acute leukemia: biological profile, clinical characteristic and treatment outcomes: report of the population-based study. Eur J Haematol. 2020;105:85–93.
5. Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X, et al. Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk Res. 2016;45:40–6.
6. Shimizu H, Saitoh T, Machida S, Kako S, Doki N, Mori T, et al. Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol. 2015;95:455–60.
7. Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019;185(6):656–69.
8. Konopleva M, Polleyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17.
9. Courteney DD, Keith P, Vindon Plbian AJ, Martha A, Pamela S, Bet al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(11):1–7.
10. Andrew HW, Pau M, Vladimir L, Courtney DD, Jan N, Kamel L, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–45.
11. Chong CC, Andrew WR, John R, Chun YF, Stephen BT, Jessica MS, et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020;38(30):3506–17.
12. Wu X, Zhang J, Chen Q, Zhou L, Li M, Qiu H, et al. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia. BJH. 2020;189(5):e200-4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.